Kyle Darnell, MD
Pulmonary Disease · Cincinnati, OHNPI 1255520524
Payments from drug & device makers
Across 270 payments — averaging $38.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$992
- AstraZeneca$654
- Inogen, Inc.$501
- Takeda Pharmaceuticals U.S.A., Inc.$353
- Sanofi$267
- plus $2K from 25 others
What the payments were for
- Consulting fees$2002%
- Travel & lodging$1,56815%
- Food & beverage$4,64845%
- Education$4,02839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $5,839 |
| GSK | 98 | $992 |
| AstraZeneca | 21 | $654 |
| Inogen, Inc. | 28 | $501 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $353 |
| Sanofi | 13 | $267 |
| Grifols USA, LLC | 11 | $219 |
| Boehringer Ingelheim | 6 | $203 |
| Bayer | 1 | $200 |
| Regeneron Healthcare Solutions, Inc. | 7 | $170 |
| Pulmonx Corporation | 6 | $148 |
| Philips North America LLC | 7 | $126 |
| United Therapeutics Corporation | 7 | $124 |
| Actelion Pharmaceuticals US, Inc. | 6 | $94 |
| Genentech USA, Inc. | 4 | $79 |
| Resmed Corp | 3 | $54 |
| Baxter Healthcare | 2 | $53 |
| Fisher & Paykel Healthcare Inc | 2 | $52 |
| Medical Device Business Services, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 3 | $40 |
| Insmed, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $13 |
| Livanova USA, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,366
- BREZTRI$351
- DA VINCI SP$292
- FASENRA$235
- Adempas$200
- TEZSPIRE$131
How this compares
$10,444 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 22 | $281,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 342 | $271,289 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 166 | $133,985 |
| Fasenra PenBenralizumab | 12 | $66,304 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $47,199 |
| Dupixent SyringeDupilumab | 12 | $43,366 |
| Spiriva HandihalerTiotropium Bromide | 52 | $28,108 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $25,332 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $24,310 |
| Spiriva RespimatTiotropium Bromide | 20 | $14,753 |
| Arnuity ElliptaFluticasone Furoate | 47 | $12,115 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $11,131 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $10,545 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 290 | $7,725 |
| Roflumilast | 43 | $4,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $992 | $355,935521 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $94 | $281,01622 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $654 | $155,661216 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $203 | $39,06252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Bruce CorserCincinnati$8.2M
- Jean ElwingCincinnati$2.4M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Mohammad SheattCincinnati$405K
- Robert BurkesCincinnati$299K
- Arun JoseCincinnati$287K
- Bruce TrapnellCincinnati$153K
- Rachel FootCincinnati$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.